A high frequent BRCA1 founder mutation identified in the Greenlandic population

Theresa Larriba Harboe; Hans Eiberg; Peder Kern; Bent Ejlertsen; Lotte Nedergaard; Vera Timmermans-Wielenga; Inge-Merete Nielsen; Marie Luise Bisgaard

doi:10.1007/s10689-009-9257-5

A high frequent BRCA1 founder mutation identified in the Greenlandic population

Theresa Larriba Harboe, Hans Eiberg, Peder Kern, Bent Ejlertsen, Lotte Nedergaard, Vera Timmermans-Wielenga, Inge-Merete Nielsen, Marie Luise Bisgaard

17 Citations (Scopus)

Abstract

Approximately 10% of all breast and ovarian cancers are dominantly inherited and mutations are mainly found in the BRCA 1 and 2 genes. The penetrance of BRCA1 mutations is reported to be between 68 and 92% and confers a 36-92% life time risk of breast cancer. Most mutations in BRCA1 are uniquely occurring mutations, but founder mutations have been described. In this study we describe a founder mutation with wide spread presence in the Inuit population. We have screened 2,869 persons from Greenland for the presence of a BRCA1 mutation (p.Cys39Gly) only found in the Inuit population. The overall carrier frequency was 1.6% in the general population, but the frequency differs geographically from 0.6% on the West coast to 9.7% in the previously isolated population of the East coast. This is to our knowledge the highest population frequency of a BRCA1 mutation ever to be described. To determine the clinical relevance of the mutation, we have examined ten breast cancer patients and nine ovarian cancer patients from Greenland for the presence of the p.Cys39Gly mutation. We found three ovarian cancer patients (33%) and one breast cancer patient (10%) carrying the mutation. The high number of women carrying a BRCA1 mutation known to trigger the development of potentially lethal diseases leads us to recommend an offer of genetic counselling and test for the mutation to all females of Inuit origin, thereby hopefully preventing a number of breast and ovarian cancer deaths.

Original language	English
Journal	Familial Cancer
Volume	8
Issue number	4
Pages (from-to)	413-9
Number of pages	6
ISSN	1389-9600
DOIs	https://doi.org/10.1007/s10689-009-9257-5
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10689-009-9257-5

Cite this

@article{d122cbe0d03b11dea1f3000ea68e967b,

title = "A high frequent BRCA1 founder mutation identified in the Greenlandic population",

abstract = "Approximately 10% of all breast and ovarian cancers are dominantly inherited and mutations are mainly found in the BRCA 1 and 2 genes. The penetrance of BRCA1 mutations is reported to be between 68 and 92% and confers a 36-92% life time risk of breast cancer. Most mutations in BRCA1 are uniquely occurring mutations, but founder mutations have been described. In this study we describe a founder mutation with wide spread presence in the Inuit population. We have screened 2,869 persons from Greenland for the presence of a BRCA1 mutation (p.Cys39Gly) only found in the Inuit population. The overall carrier frequency was 1.6% in the general population, but the frequency differs geographically from 0.6% on the West coast to 9.7% in the previously isolated population of the East coast. This is to our knowledge the highest population frequency of a BRCA1 mutation ever to be described. To determine the clinical relevance of the mutation, we have examined ten breast cancer patients and nine ovarian cancer patients from Greenland for the presence of the p.Cys39Gly mutation. We found three ovarian cancer patients (33%) and one breast cancer patient (10%) carrying the mutation. The high number of women carrying a BRCA1 mutation known to trigger the development of potentially lethal diseases leads us to recommend an offer of genetic counselling and test for the mutation to all females of Inuit origin, thereby hopefully preventing a number of breast and ovarian cancer deaths.",

author = "Harboe, {Theresa Larriba} and Hans Eiberg and Peder Kern and Bent Ejlertsen and Lotte Nedergaard and Vera Timmermans-Wielenga and Inge-Merete Nielsen and Bisgaard, {Marie Luise}",

year = "2009",

doi = "10.1007/s10689-009-9257-5",

language = "English",

volume = "8",

pages = "413--9",

journal = "Familial Cancer",

issn = "1389-9600",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - A high frequent BRCA1 founder mutation identified in the Greenlandic population

AU - Harboe, Theresa Larriba

AU - Eiberg, Hans

AU - Kern, Peder

AU - Ejlertsen, Bent

AU - Nedergaard, Lotte

AU - Timmermans-Wielenga, Vera

AU - Nielsen, Inge-Merete

AU - Bisgaard, Marie Luise

PY - 2009

Y1 - 2009

N2 - Approximately 10% of all breast and ovarian cancers are dominantly inherited and mutations are mainly found in the BRCA 1 and 2 genes. The penetrance of BRCA1 mutations is reported to be between 68 and 92% and confers a 36-92% life time risk of breast cancer. Most mutations in BRCA1 are uniquely occurring mutations, but founder mutations have been described. In this study we describe a founder mutation with wide spread presence in the Inuit population. We have screened 2,869 persons from Greenland for the presence of a BRCA1 mutation (p.Cys39Gly) only found in the Inuit population. The overall carrier frequency was 1.6% in the general population, but the frequency differs geographically from 0.6% on the West coast to 9.7% in the previously isolated population of the East coast. This is to our knowledge the highest population frequency of a BRCA1 mutation ever to be described. To determine the clinical relevance of the mutation, we have examined ten breast cancer patients and nine ovarian cancer patients from Greenland for the presence of the p.Cys39Gly mutation. We found three ovarian cancer patients (33%) and one breast cancer patient (10%) carrying the mutation. The high number of women carrying a BRCA1 mutation known to trigger the development of potentially lethal diseases leads us to recommend an offer of genetic counselling and test for the mutation to all females of Inuit origin, thereby hopefully preventing a number of breast and ovarian cancer deaths.

AB - Approximately 10% of all breast and ovarian cancers are dominantly inherited and mutations are mainly found in the BRCA 1 and 2 genes. The penetrance of BRCA1 mutations is reported to be between 68 and 92% and confers a 36-92% life time risk of breast cancer. Most mutations in BRCA1 are uniquely occurring mutations, but founder mutations have been described. In this study we describe a founder mutation with wide spread presence in the Inuit population. We have screened 2,869 persons from Greenland for the presence of a BRCA1 mutation (p.Cys39Gly) only found in the Inuit population. The overall carrier frequency was 1.6% in the general population, but the frequency differs geographically from 0.6% on the West coast to 9.7% in the previously isolated population of the East coast. This is to our knowledge the highest population frequency of a BRCA1 mutation ever to be described. To determine the clinical relevance of the mutation, we have examined ten breast cancer patients and nine ovarian cancer patients from Greenland for the presence of the p.Cys39Gly mutation. We found three ovarian cancer patients (33%) and one breast cancer patient (10%) carrying the mutation. The high number of women carrying a BRCA1 mutation known to trigger the development of potentially lethal diseases leads us to recommend an offer of genetic counselling and test for the mutation to all females of Inuit origin, thereby hopefully preventing a number of breast and ovarian cancer deaths.

U2 - 10.1007/s10689-009-9257-5

DO - 10.1007/s10689-009-9257-5

M3 - Journal article

C2 - 19504351

SN - 1389-9600

VL - 8

SP - 413

EP - 419

JO - Familial Cancer

JF - Familial Cancer

IS - 4

ER -

A high frequent BRCA1 founder mutation identified in the Greenlandic population

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this